Study: Single daily ribavirin dose doesn't increase adverse effects

03/27/2013 | Medscape (free registration)

Researchers at the Icahn School of Medicine at Mount Sinai in New York found once-daily ribavirin treatment did not increase the risk of adverse gastrointestinal events in hepatitis C patients being treated with triple therapy. The results were presented at the International Conference on Viral Hepatitis.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY